Drug name: Thioridazine
Related CSCTT Targets
| Dopamine receptor D5 [ref.1] | P21918 |
Thioridazine
| Cas.no | PubChem ID |
| 50-52-2 | 5452 |
| Known Target | |
| 50S ribosomal protein L24e | P14116 |
| D(1A) dopamine receptor | P21728 |
| Alpha-1A adrenergic receptor | P35348 |
| Alpha-1B adrenergic receptor | P35368 |
| 5-hydroxytryptamine receptor 2A | P28223 |
| Potassium voltage-gated channel subfamily H member 2 | Q12809 |
| Introduction | |
| A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. | |
Thioridazine-Structure
Reference
- [1] Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Sachlos, E., et al. (2012).Cell. 149(6):1284-97.
22632761. [ 22632761 ]